Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week [Seeking Alpha]
Vanda Pharmaceuticals Inc. (VNDA)
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=196233&p=irol-irhome
Company Research
Source: Seeking Alpha
VNDA's valuation is deeply discounted, trading at 1.4x forward sales and 0.5x EV/sales, reflecting high regulatory and execution risk. Upcoming catalysts include the Nereus launch and Bysanti's PDUFA decision; approval could diversify revenues but is far from guaranteed. I downgrade to a Hold rating due to aggressive spending, cash burn, and significant uncertainty around Bysanti's regulatory outcome. Jonathan Kitchen/DigitalVision via Getty Images Thesis Vanda Pharmaceuticals Inc. ( VNDA ) disappointed the market with a pretty weak 4Q25. They reported a GAAP EPS of -$2.39, which missed consensus by about $1.07, and a revenue figure of $57.22 million that came in about $2.05 million This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receivi
Show less
Read more
Impact Snapshot
Event Time:
VNDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNDA alerts
High impacting Vanda Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VNDA
News
- Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric InnovationPR Newswire
- Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Vanda Pharmaceuticals Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=VNDA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
VNDA
Earnings
- 2/11/26 - Miss
VNDA
Sec Filings
- 2/19/26 - Form 4
- 2/19/26 - Form 4
- 2/19/26 - Form 4
- VNDA's page on the SEC website